A National Cancer Institute-designated Comprehensive Cancer Center

Make an appointment: 800-826-HOPE

Zeng, Defu, M.D. Research

Defu Zeng, M.D. Research
Transplantation Immune Tolerance
Allogeneic hematopoietic cell transplantation (HCT) is a curative therapy for hematological malignancies and hereditary disorders as well as refractory autoimmune diseases. Induction of mixed chimerism via allogeneic HCT is also one of the most reliable approaches for induction of organ transplantation tolerance. However, graft-versus-host disease (GVHD) remains a major obstacle in classical HCT, in which recipients are required to be conditioned with total body irradiation (TBI) or high dose chemotherapy in order to allow donor stem cell engraftment. Recent studies have shown that tissue damage and activation of tissue dendritic cells caused by conditioning TBI or chemotherapy plays a critical role in induction of GVHD.
One of the research projects in the Zeng lab is to understand the pathogenesis of GVHD, in which donor T cells infiltrate the target tissues and mediate damage. Based on the clinical features, GVHD can be divided into acute and chronic GVHD. New immunosuppressants have been effective in preventing acute but not chronic GVHD. The latter remains the major cause of morbidity and mortality of long-term survivors of classical HCT, and there has been no improvement in treating chronic GVHD over the past three decades, due to the poor understanding of its pathogenesis.
We have recently developed new mouse models of chronic GVHD that can reflect the pathogenesis in humans. We are currently dissecting the role of allo- and auto-reactive CD4+ T (Th1, Th2 and Th17), Treg cells, APCs (dendritic and B cells), as well as autoantibodies in the pathogenesis of chronic GVHD. We are currently testing whether depletion of donor CD4+ T cells and/or B cells early after HCT can prevent chronic GVHD. These studies will provide new insights into chronic GVHD pathogenesis and lead to the development of novel therapies for patients.
Another project is to develop a radiation-free GVHD preventative conditioning regimen for induction of mixed chimerism for the therapy of autoimmune diseases (i.e. type 1 diabetes, multiple sclerosis, and lupus). We have observed that induction of mixed chimerism results in reversal of autoimmunity, elimination of insulitis, and beta cell regeneration in overt diabetic NOD mice. We are dissecting the mechanisms whereby mixed chimerism reverses autoimmunity. We are also tracing the origin of beta cell regeneration after reversal of autoimmunity. Our studies will provide new insights into transplantation biology and promote the application of HCT as a curative therapy not only for patients with hematological malignancies but also for patients with variety of refractory autoimmune diseases.

Lab Members

Defu Zeng, M.D.
626-246-HOPE (4673) ext. 62587
Ruishu Deng, M.D., Ph.D.
Postdoctoral Fellow
626-246-HOPE (4673) ext. 64432
Mingfeng Zhang, Ph.D.
Postdoctoral Fellow
626-246-HOPE (4673) ext. 64203
Jeremy Racine, Ph.D.
Postdoctoral Fellow
626-246-HOPE (4673) ext. 63713
Ya-Jing Xu, M.D.
Visiting Scientist
626-246-HOPE (4673) ext. 64332
Heather Johnston
Ph.D. candidate
626-246-HOPE (4673) ext. 62912
Xiong Ni
Ph.D. candidate
626-246-HOPE (4673) ext. 61036
Kaniel Cassady
Ph.D. student
626-246-HOPE (4673) ext. 64432
Hua Jin
International Ph.D. student
626-246-HOPE (4673) ext. 60659
Our Scientists

Our research laboratories are led by the best and brightest minds in scientific research.

Beckman Research Institute of City of Hope is internationally  recognized for its innovative biomedical research.
City of Hope is one of only 41 Comprehensive Cancer Centers in the country, the highest designation awarded by the National Cancer Institute to institutions that lead the way in cancer research, treatment, prevention and professional education.
Learn more about City of Hope's institutional distinctions, breakthrough innovations and collaborations.
Develop new therapies, diagnostics and preventions in the fight against cancer and other life-threatening diseases.
Support Our Research
By giving to City of Hope, you support breakthrough discoveries in laboratory research that translate into lifesaving treatments for patients with cancer and other serious diseases.
  • The burgeoning type 2 diabetes epidemic casts a pall over the health of America’s public. New research now shows the looming threat is getting worse. Much worse. A diabetes trends study published earlier this mongh in the Lancet Diabetes and Endocrinology by researchers at the federal Centers for Disease Contro...
  • An aspirin a day might help keep breast cancer away for some breast cancer survivors, a new study suggests. Obese women who have had breast cancer could cut their risk of a recurrence in half if they regularly take aspirin or other nonsteroidal anti-inflammatory drugs, called NSAIDs, report researchers from the...
  • Christine Crews isn’t only a fitness enthusiast, she’s also a personal trainer and fitness instructor. Being active defines her life. So when she was diagnosed with bladder cancer at age 30, she decided she absolutely couldn’t let the disease interfere with that lifestyle. And it didn’t. For t...
  • Cancer treatment and the cancer itself can cause changes in your sense of taste or smell. These side effects typically subside after treatment ends, but there are ways to help alleviate those bitter and metallic tastes in your mouth. Here are tips from the National Cancer Institute to help keeps tastes and food...
  • Immunotherapy — using one’s immune system to treat a disease — has been long lauded as the “magic bullet” of cancer treatments, one that can be more effective than the conventional therapies of surgery, radiation or chemotherapy. One specific type of immunotherapy, called adoptive T cell thera...
  • Today, when cancer spreads from its original site to other parts of the body, a process known as metastasis, patients face an uphill battle. Treatments are poorly effective, and cures are nearly impossible. Further, incidence rates for these types of cancers are increasing – particularly for cancers that have s...
  • Thanks to the California Institute for Regenerative Medicine (CIRM), high school students across the state gained valuable hands-on experience with stem cell research this summer. City of Hope hosted eight of those students. As part of the CIRM Creativity Awards program, the young scholars worked full time as m...
  • Radiation therapy can help cure many children facing Hodgkin lymphoma and other cancers. When the radiation is delivered to a girl’s chest, however, it can lead to a marked increase in breast cancer risk later in life. A recent multi-institutional study that included City of Hope’s Smita Bhatia, M.D., M.P.H., t...
  • A patient diagnosed with cancer – especially a rare, advanced or hard-to-treat cancer – needs specialized care from exceptionally skilled and highly trained experts. That kind of care saves lives, improves quality of life and keeps families whole. That kind of care is best found at comprehensive cancer centers ...
  • Appetite loss may be common during cancer treatment, lasting throughout your therapy or only occasionally, but it can be managed. Below are tips from the National Cancer Institute (NCI) that can help you keep your weight up and, in doing so, keep your body well-nourished. (See the end of this article for a deli...
  • Myelodysplasia, sometimes referred to as myelodysplastic syndrome or MDS, is a rare group of blood disorders caused by disrupted development of blood cells within the bone marrow, resulting in a decreased number of healthy blood cells. People diagnosed with the condition, considered a precancer, may be at great...
  • Twenty years ago, scientists discovered that a mutation in a gene now widely known as BRCA1 was linked to a sharply increased risk of breast cancer, paving the way for a new chapter in identifying women at risk of the disease and giving them options to potentially avoid an aggressive cancer. But experts have al...
  • The Eugene and Ruth Roberts Summer Student Academy at City of Hope turned 54 this year. Marking the occasion, the academy announced a new scholarship in honor of longtime director Paul Salvaterra, Ph.D. Salvaterra, a professor in City of Hope’s Department of Neurosciences, has led the summer student acade...
  • Stevee Rowe has a very personal connection to the research she’s conducting on neural stem cells: Her late father participated in a City of Hope clinical trial involving neural stem cells. Rowe — her full name is Alissa Stevee Rowe, but she prefers to use her middle name — will enter her senior year at the [...
  • Although multiple myeloma is classified as a blood cancer, patients with this disease often experience bone-related symptoms, too. This includes bone pain, frequent fractures and spots of low bone density or bone damage that show up during a skeletal scan. Here, Amrita Krishnan, M.D., director of City of Hope&#...